Table 1.
Demographic and laboratory characteristics of enrolled individuals.
| Pre-vaccination | Post-vaccination | Reference | |
|---|---|---|---|
| Age (median, Q1–Q3, years) | 36 (29–44) | ||
| Sex (F/M) | 312/94 | ||
| Laboratory assay | |||
| Leukocytes (× 109/L) | 6.27 (5.17–7.40) | 6.37 (5.30–7.40) | 3.69–9.16 |
| Red blood cell (× 1012/L) | 4.45 (4.21–4.80) | 4.46 (4.17–4.80) | 3.68–5.13 |
| Hemoglobin (g/L) | 133 (125–143) | 133 (124–143) | 113–151 |
| Platelet count (× 109/L) | 255 (220–290) | 259 (222–293) | 101–320 |
| Aspartate aminotransferase (IU/L) | 22 (20–27) | 20 (16–25) | 8–40 |
| Alanine aminotransferase (IU/L) | 16 (13–23) | 17 (3–25) | 10–64 |
| Total bilirubin | 8.2 (6.4–10.4) | 7.8 (6.1–10.2) | 4.7–24.0 |
| Albumin | 45 (43–47) | 43 (31–45) | 35–55 |
| Seroconversion rate of SARS-CoV-2 specific antibodies | 0 (0%) | 389 (95.81) | |
| Adverse reactions, n (%) | / | 225 (55.42) | |
| Systemic adverse reactions | / | 155 (38.18) | |
| Fever | / | 11 (2.71) | |
| Dizziness and headache | / | 56 (13.79) | |
| Fatigue | / | 104 (25.62) | |
| Diarrhea | / | 25 (6.16) | |
| Constipation | / | 0 | |
| Nausea and vomiting | / | 20 (4.93) | |
| Noninoculation site muscle and joint pain | / | 6 (1.48) | |
| Abnormal skin and mucosa | / | 13 (3.20) | |
| Local adverse reactions | / | 133 (32.76) | |
| Pain and tenderness | / | 120 (29.56) | |
| Lumps and swelling | / | 28 (6.90) | |
| Rash | / | 7 (1.72) | |
| Redness | / | 40 (9.85) | |
| Other adverse events | / | 26 (6.40) |